Trial Profile
A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 [preladenant] in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms [extrapyramidal disorders] Among Subjects With Schizophrenia and Schizoaffective Disorders
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Preladenant (Primary)
- Indications Antipsychotic-induced movement disorders
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 20 Jun 2008 New trial record.